2 Minute Read
A study at the Western General Hospital in Edinburgh, UK sought to discover the relationship between adalimumab drug levels and biologic remission during maintenance therapy for Crohn’s disease.
Using the IDKmonitor® Adalimumab Drug Level ELISA and IDKmonitor® Adalimumab Total ADA ELISA, researchers collected data on adalimumab drug and antibody levels in patients with Crohn’s disease who received adalimumab therapy and analyzed these values with respect to the severity of the disease.
The researchers found that patients in biologic remission from Crohn’s disease had significantly higher adalimumab values.
Biomarker Background: Adalimumab
Adalimumab is a biological therapy drug that acts as a tumor necrosis factor-alpha (TNFα) inhibitor. Because TNFα causes inflammation, an overabundance of it can lead to conditions like Crohn’s disease or ulcerative colitis, among others.
Adalimumab is used to treat these conditions and reduce the level of inflammation which can lead to symptoms.
Learn More About the IDKmonitor® Adalimumab ELISAs
Do you have technical questions about any of the IDKmonitor® Adalimumab ELISAs? Our Support Team is here to help you!
Contact us to get started.
Featured Kits: IDKmonitor® Adalimumab ELISAs
- For the Determination of Free Adalimumab, Total ADA or Free ADA Against TNFα Antibody Adalimumab
- EDTA Plasma or Serum
- Health Canada Licensed
- Research Use Only in the U.S.